FIELD: biotechnology.
SUBSTANCE: described is a combination for treating a tumour, wherein the composition contains an oncolytic adenovirus, a CDK4/6 inhibitor and nutlin or a nutlin derivative, wherein the oncolytic adenovirus expresses the E1A12S protein and does not express the E1A13S protein. Also described is a method of treating a tumour, according to which an oncolytic adenovirus, a CDK4/6 inhibitor and nutlin or a nutlin derivative are administered to a subject, wherein the oncolytic adenovirus expresses the E1A12S protein and does not express the E1A13S protein.
EFFECT: invention extends the range of agents for treating tumours.
32 cl, 91 dwg, 1 tbl, 35 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF TUMORS WITH A COMBINATION OF ONCOLYTIC ADENOVIRUS AND CDK4/6 INHIBITOR | 2019 |
|
RU2811278C2 |
| ONCOLYTIC ADENOVIRUSES ENCODING BISPECIFIC ANTIBODIES, AS WELL AS METHODS AND APPLICATIONS ASSOCIATED THEREWITH | 2016 |
|
RU2725799C2 |
| ADENOVIRUS WITH DIRECTED GENE EXPRESSION AND USE THEREOF | 2003 |
|
RU2393221C2 |
| CEREBRAL CANCER TREATMENT WITH ONCOLYTIC ADENOVIRUS | 2014 |
|
RU2689553C2 |
| EXTENDED ADOPTIVE CELL THERAPY | 2014 |
|
RU2703438C2 |
| METHODS OF TREATING CDK4/6 INHIBITOR-RESISTANT CANCER | 2019 |
|
RU2820478C2 |
| ADENOVIRUS CONTAINING ALBUMIN-BINDING SITE | 2015 |
|
RU2711371C2 |
| METHODS OF TREATING AR+ BREAST CANCER | 2017 |
|
RU2769527C2 |
| MODIFIED ONCOLYTIC ADENO VIRUSES | 2019 |
|
RU2788638C2 |
| ADENOVIRAL VECTORS AND RELATED METHODS AND APPLICATIONS | 2009 |
|
RU2520823C2 |
